Source comparison
Comparison: BPC-157 vs Standard Tendon Injury Treatments
BPC-157 Upregulates VEGF/TGF-β1 receptors; promotes angiogenesis and collagen synthesis Animal models only (no human RCTs) 60–80% faster in rat studies (4–6 weeks vs 6–10 weeks) Strong biological plausibility; zero human trial data limits clinical applicabilit
This comparison does not assign a generated winner or score.
- BPC-157
- Upregulates VEGF/TGF-β1 receptors; promotes angiogenesis and collagen synthesis
- Animal models only (no human RCTs)
- 60–80% faster in rat studies (4–6 weeks vs 6–10 weeks)
- Strong biological plausibility; zero human trial data limits clinical applicability
- Platelet-Rich Plasma (PRP)
- Autologous growth factor delivery from concentrated platelets
- Mixed human trial data; some RCTs show benefit, others show no difference vs placebo
- 10–20% faster healing in responsive cases (12–14 weeks vs 14–16 weeks)
- FDA-cleared procedure; moderate evidence quality; effect size smaller than expected from mechanism
- Physical Therapy + Eccentric Loading
- Mechanotransduction stimulates collagen remodelling; progressive load increases tensile strength
- Strong RCT evidence across tendinopathies
- Standard 12–16 week timeline; improves functional outcomes and reduces re-injury risk
- Gold standard non-surgical intervention; supported by systematic reviews and meta-analyses
- NSAIDs + Rest
- Reduces inflammation and pain; passive healing
- Well-studied but controversial for tendon healing (may impair collagen synthesis)
- 14–18 weeks; pain relief within days but healing timeline unchanged
- Pain management only; does not accelerate biological repair and may slow it
- The comparison underscores BPC-157's unique position: its proposed mechanism is more aggressive than passive rest and more targeted than systemic anti-inflammatories, but the evidence quality is orders of magnitude lower than established interventions like eccentric loading protocols.